We have engaged both local counsel and counsel in Singapore, where any arbitration action would need to take place.
IMO they will never proceed past the "hype Mundipharma in a newsletter" phase -- Staelin just needed a high-dollar item in his newsletter to cover up the fact that there were no big orders in 2024 (yet). $14 million is shiny.
The contract wording would be fun to examine but we'll never see it. I can't believe that Mundipharma would contractually agree to buying $14 million of a product they've never sold before, with wording that if they failed to buy $14 million worth they'd be legally obligated to pay the remainder, or even a penalty. It just looked like another distribution agreement when BIEL released the PR in 2018:
All it says is that Mundipharma acquired distribution rights. Nothing to indicate that MundiPharma legally agreed to pay $14 million. That would have been BIG news in 2018 if true. Suspicious that BIEL didn't pump the $14 million back then. "Intent" goes a long way in a court of law.
It's just arbitration, not a lawsuit. Maybe BIEL will pursue this. At least it's SOMETHING to talk about.